Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma

Chinese Journal of Oncology

Volumn 36, Issue 9, 2014, Pages 662-666

  Tang, Xiaolong ^a   Zhang, Jianwei ^a   Chen, Yingtai ^a   Lan, Zhongmin ^a   Wang, Chengfeng ^a  

^a CANCER HOSPITAL   (China)

Author keywords

CA19 9; CEA; Cholangiocarcinoma; Clinieopathological features; Extrahepatic

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CLINICAL FEATURE; CORRELATIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EXTRAHEPATIC CHOLANGIOCARCINOMA; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; TUMOR DIFFERENTIATION; TUMOR INVASION; BILE DUCT TUMOR; INTRAHEPATIC BILE DUCT; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHOLANGIOCARCINOMA; HUMANS; LYMPHATIC METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84928992221     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2014.09.005     Document Type: Article

References (9)

1. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United Slates: a population-based case-control study [J]. Clin Gastroenterol Hepatol, 2007, 5(10): 1221-1228.
2. Cardinale V, Semeraro R, Torrice A, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors[J]. World J Gastrointest Oncol, 2010, 2(11):407-416.
3. Yusoff AR, Razak MM, Yoong BK, et al. Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia[J]. World J Gastroenterol, 2012, 18(5):458-465.
4. Gores GJ Early detection and treatment of cholangiocarcinoma [J]. liver Transpl, 2000, 6(6 Suppl 2):S30-34.
5. Blechacz B, Komuta M, Roskams T, et al. Clinical diagnosis and staging of cholangiocarcinoma[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(9):512-522.
6. John AR, Haghighi KS, Taniere P, et al. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? [J]. Dig Surg, 2006, 23 (5-6):319-324.
7. Juntermanns B, Radunz S, Heuer M, et al. Tumor markers as a diagnostic key for hilar cholangiocarcinoma[J]. Eur J Med Res, 2010, 15(8):357-361.
8. Venkatesh PG, Navaneethan U, Shen B, et al. Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma [J]. Dig Dis Sei, 2013, 58(3):850-857.
9. Jablońska B. Biliary cysts: etiology, diagnosis and management [J]. World J Gastroenterol, 2012, 18(35):4801-4810.